Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Table 3

Lenalidomide containing regimens in relapsed/refractory indolent and mantle cell lymphoma.

Author	Year	Phase	Histology	𝑛	Age (range)	Previous CT	Combination	ORR (%)	CR (%)
Wang et al. [27]	2007	I/II	MCL	15	73 (62–84)	2 (1–7)	RL	83^*	17^*
Dutia et al. [28]	2009	II	Indolent NHL	15	60 (50–91)	4 (1–11)	RL	83.3	41
Zaja et al. [29]	2011	II	MCL	33	68 (51–80)	3 (2–7)	LD	52	24

^*: data from patients enrolled in lenalidomide 20 mg/daily arm. No response was obtained for lower dosage.
CT: chemotherapy; ORR: overall response rate; CR: complete response; RL: rituximab and lenalidomide; LD: lenalidomide and dexamethasone.